Parallax Volatility Advisers, L.P. Prothena Corp Public LTD CO Transaction History

Parallax Volatility Advisers, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $310,070 - $504,940	6,425 New	6,425 $438,000
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $283,005 - $389,832	-27,965 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$9.93 - $13.47 $277,692 - $376,688	27,965 New	27,965 $279,000
Q1 2019 May 15, 2019	SELL	$10.32 - $14.49 $1,042 - $1,463	-101 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$8.73 - $13.74 $61,974 - $97,540	-7,099 Reduced 98.6%	101 $1,000
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $352,298 - $438,014	-27,740 Reduced 79.39%	7,200 $94,000
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $508,760 - $2.05 Million	-46,293 Reduced 56.99%	34,940 $509,000
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $2.1 Million - $3.39 Million	75,311 Added 1271.72%	81,233 $2.98 Million
Q4 2017 Feb 14, 2018	BUY	$35.44 - $63.76 $209,875 - $377,586	5,922	5,922 $222,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.